GlassScriptPhysician profile
Sara M Gordon
NPI 1902046808
$1,347.08
in general payments reported to CMS, 2019-2025
15 companies · $96.77 in 2025
The $96.77 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $317 · 2020: $71.37 · 2021: $148 · 2022: $218 · 2023: $228 · 2024: $267 · 2025: $96.77.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $592.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $592.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $200.36 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $188.56 | 2019-2025 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $158.87 | 2019-2021 | |
| Allergan, INC. | $158.09 | 2019-2022 | |
| Coopervision INC. | $113.61 | 2021-2023 | Myday Contact Lens |
| Oyster Point Pharma, INC. | $113.27 | 2022-2025 | Tyrvaya, Ryzumvi |
| Hoffmann-La Roche Limited | $104.82 | 2019 | |
| Bausch & Lomb Americas INC. | $73.35 | 2023-2025 | Miebo, Vyzulta, Xiidra |
| Tarsus Pharmaceuticals, INC. | $59.44 | 2024 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $57.00 | 2022-2023 | |
| Alcon Vision LLC | $51.81 | 2023-2024 | Rocklatan, Total30 |
| Optovue, INC. | $23.43 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $18.27 | 2021 | |
| Shire North American Group INC | $14.42 | 2019 | |
| Kala Pharmaceuticals, INC. | $11.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.